Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Citi
US Department of Justice
Accenture
Merck
Farmers Insurance
Mallinckrodt
Fuji
US Army
McKinsey

Generated: October 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,740,669

« Back to Dashboard

Which drugs does patent 6,740,669 protect, and when does it expire?


Patent 6,740,669 protects BANZEL and is included in two NDAs. There have been two Paragraph IV challenges on Banzel.

Protection for BANZEL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 6,740,669

Title: Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic
Abstract:The invention relates to the novel modification A or A' of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula ##STR1## its use and pharmaceutical preparations comprising this crystal modification.
Inventor(s): Portmann; Robert (Pratteln, CH), Hofmeier; Urs Christoph (St. Pantaleon, CH), Burkhard; Andreas (Basel, CH), Scherrer; Walter (Rheinfelden, CH), Szelagiewicz; Martin (Munchenstein, CH)
Assignee: Novartis AG (Basel, CH)
Application Number:09/125,329
Patent Claim Types:
see list of patent claims
Compound; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Eisai Inc
BANZEL
rufinamide
TABLET;ORAL021911-001Nov 14, 2008DISCNYesNo► Subscribe► SubscribeY
Eisai Inc
BANZEL
rufinamide
TABLET;ORAL021911-002Nov 14, 2008ABRXYesNo► Subscribe► SubscribeY
Eisai Inc
BANZEL
rufinamide
TABLET;ORAL021911-003Nov 14, 2008ABRXYesYes► Subscribe► SubscribeY
Eisai Inc
BANZEL
rufinamide
SUSPENSION;ORAL201367-001Mar 3, 2011RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,740,669

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Switzerland1404/97Jun 10, 1997
PCT Information
PCT FiledJune 08, 1998PCT Application Number:PCT/EP98/03427
PCT Publication Date:December 17, 1998PCT Publication Number: WO98/56772

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Argus Health
McKesson
Harvard Business School
Merck
Julphar
Cipla
Federal Trade Commission
Express Scripts
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot